DLA Piper Represents Liquidia Corporation in US$100 Million Revenue Interest Financing Agreement
DLA Piper represented biopharmaceutical company Liquidia Corporation in its revenue interest financing agreement with HealthCare Royalty, a leading royalty acquisition company focused on commercial or near-commercial stage biopharmaceutical products, for a total investment amount of US$100 million.
The biopharmaceutical company intends to use the proceeds from the financing to further develop its YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension. The proceeds will also support the continued clinical development of YUTREPIA and provide capital business development activities directed towards expanding Liquidia’s product pipeline.
“We are proud to support Liquidia as they continue pursuing a critical treatment for an ailment that afflicts so many people,” said Andrew Gilbert, co-chair of DLA Piper’s Life Sciences sector who co-led the deal. “We’re excited to see the progress they make with this essential funding, and we look forward to supporting their future endeavors, as well as other advancements within the industry.”
In addition to Gilbert (Short Hills), the DLA Piper team representing Liquidia was co-led by partner Lauren Murdza (Philadelphia) and it included partner Tonya Major Gauff (Chicago), and associates Dylan Caplan (Philadelphia), John Wei (Boston), and Nicholas Luciano (Short Hills).
DLA Piper advises on all aspects of the life sciences sector, combining subject matter experience with considerable knowledge of the scientific, medical, regulatory, commercial and enforcement environments facing biopharmaceutical, medical device, research and diagnostics clients. Recognizing that clients’ needs vary, the firm rapidly organizes and customizes client service teams, whether for a large pharmaceutical company, a mid-sized medical device client or a development-stage biotech company.